Doximity Stock Surges 32% on AI Tool Profitability

Doximity's stock performance reflects investor enthusiasm for the company's AI monetization strategy. While the company reported modest top-line growth—revenue rose 7% year-over-year to $156.6 million in fiscal 2027 Q1—and declining adjusted EBITDA (down 6% to $74.8 million), the narrative shifted decisively when management detailed the economics of its AI products. The independent validation of Doximity Ask's clinical performance appears to have resolved investor concerns about whether the company's substantial AI spending would translate into tangible competitive advantages.

Tangney's disclosure that AI Search generates over 10x return on investment per query, combined with evidence of sharp usage growth (AI prompt volume up 25% quarter-on-quarter, Scribe users up 10x in July), paints a picture where near-term margin pressure may be offset by genuine unit economics. The CEO's comment that operating costs could decline further as models become more efficient suggests Doximity expects profitability to improve as the business scales, which may explain why investors rushed to bid up the stock despite the current quarter's EBITDA decline.